This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Both the Pfizer and Moderna vaccines copied RNA sequence from the virus genome and found a way to manufacture it at scale with high-level processes and quality control. Let’s also remember that pharma is going to make a LOT of money on these vaccines. The post How did pharma develop a vaccine so quickly?
to establish a manufacturing plant as it progresses on its radiopharma journey. The site marks the world’s first industrial-scale facility dedicated to production of lead-212-based radioligand therapies, the company said. Amid a nuclear medicine boom, France’s Orano Med has chosen the U.S.
Three Japanese pharma companies lead our news stories from Asia this week. And Takeda is ordered to pay AbbVie nearly $480 million because of a manufacturing hiccup. Astellas has abandoned its challenge against the Inflation Reduction Act. Astellas has abandoned its challenge against the Inflation Reduction Act.
As the emphasis of new drug development gravitates towards new, ground-breaking therapies and vaccines, the requirements of manufacturing sites, equipment and processes need to be appropriate for this new environment. That is because of the relative expense of emerging therapies and the pressure on pricing for continuing product lines.
[Yangzhou, China - March 26, 2024] - Aurisco Pharmaceutical, a leading global pharmaceutical company, is excited to announce the completion of its investment in cGMP peptide manufacturing capacity | Aurisco Pharmaceutical Launches State-of-the-Art Manufacturing Facility for GLP-1 Peptides
The turbulence of the last three years can make it seem as though pharmamanufacturers have been operating in an atmosphere of non-stop crisis. The net effect has been to stimulate change in every aspect of the pharma industry – an industry not exactly known for its embrace of manufacturing innovation.
I continue to believe that there are very good people who care about patients working within pharma but it’s hard to understand how anyone who works for AbbVie can feel good about their employer. leading to an almost $1.4 ” The post AbbVie continues to be what’s wrong with big pharma. AbbVie exploits the U.S.
Despite the promise of cell therapies, manufacturing the personalized medicines at scale has been a limiting factor for many companies. Despite the promise of cell therapies, manufacturing the personalized medicines at scale has been a limiting factor for many companies.
Olivia Gannon, Associate Director of Global MES and Digital Execution Systems, Life Sciences Manufacturing, Cognizant, explores how a digitalization strategy harnessing the latest innovatio | Olivia Gannon, Global MES Service Line Lead at Cognizant, explores how a digitalization strategy harnessing the latest innovations in MES technologies can help (..)
The Index noted companies are increasingly engaging in NEVLs, whereby multiple generic manufacturers are authorised by the patent holder (pharmaceutical company) to develop and manufacture low-cost generic versions of patented medicines, often in different countries. Three more companies now engage in at least one voluntary licence.
A new state-of-the-art manufacturing facility for microbiome ecosystem therapies has now completed construction. With the manufacturing infrastructure finished, the transfer of MaaT Pharma’s Production and Development teams to the new site has also taken place.
Two of ZS’ major studies suggest that the trend towards more advanced KAM strategies and capabilities will continue to accelerate for pharmamanufacturers. How should leadingpharma companies respond? Consolidation among providers continues unabated, leading to larger and larger health systems.
International companies investing in the emerging market of Brazilian pharmaceutical manufacturing will see a higher return on investment than from developed market equivalents, if they choose to compete with local manufacturers to supply Brazil’s growing market and the greater South American region.
September 2023 saw a wave of new pharmaceutical manufacturing facility expansions and launches across Europe. Importantly, each site features advanced technologies to support development and manufacture of these therapeutics. Materials and financing costs are high and squeezing manufacturers and their customers alike.
Results from CPhI’s 2022 Pharma Index survey , announced at this year’s CPhI Frankfurt, showed pharma confidence in growth , innovation and manufacturing quality has reached record highs, promising positive prospects for the industry in 2023 and beyond. Key countries. Scores this year were the highest on record ( Figure 2 ).
Following the UK government’s recent announcement of a £520 million funding boost for UK manufacturing, a new Oligonucleotide Manufacturing Innovation Centre of Excellence in Scotland will develop innovative and sustainable techniques for these medicines. This is a first-of-its-kind collaboration for the pharma industry.
The UK-based Centre for Process Innovation (CPI) has opened its £88 million Medicines Manufacturing Innovation Centre in Glasgow, Scotland, to help accelerate medicine development by focusing on small molecule and fine chemical manufacturing and sustainable manufacturing. The facility is part of CPI’s series of ?‘Grand
million collaboration between the Centre for Process Innovation (CPI), AstraZeneca, Novartis, and The University of Manchester aims to revolutionise oligonucleotide manufacture. The three-year project is planned to translate “…approaches to oligonucleotide synthesis into sustainable manufacturing processes.
The inventory position of 28 major pharmaceutical manufacturers in 2022 has been revealed in an annual report. Analysis explored the impact of macro-trends on inventory management from corporate reports of Big Pharma companies including Merck, AstraZeneca and Pfizer. Sales grew by seven percent, totalling $994 billion in 2022.
Crucially, January 2023 marked a key moment: the Medicines and Healthcare products Regulatory Agency (MHRA) granted Celadon Pharmaceuticals the first good manufacturing practice (GMP) registration since legalisation in 2018 for high Δ9-tetrahydrocannabinol (THC) cannabis active pharmaceutical ingredient (API).
There has been a steady stream of developments in the vaccine manufacturing space throughout 2023. A notable milestone was Moderna’s announcement in April that it had, following finalisation of a ten-year strategic partnership with the UK Government, commenced construction of its mRNA vaccine manufacturing technology centre.
The pharmaceutical industry is becoming increasingly conscious of emissions and the importance of sustainable manufacturing. 1 Every major pharmaceutical manufacturer in the UK and Ireland is investing in making their operations and supply chains more environmentally friendly.
A market report has projected that the global oral solid dosage (OSD) contract manufacturing market is expected to be worth $54.7 Data showed that worldwide, oral solids are the most popular mode of drug delivery due to being highly cost-effective and offering simple manufacturing processes.
A new global Minimized Risk of Antimicrobial Resistance (AMR) certification has been launched to promote and demonstrate responsible antibiotic manufacturing in the global pharmaceutical supply chain. BSI, a UK standards body, developed the new certification to the Antibiotic Manufacturing Standard published in June 2022.
Dubbed the Advanced Thorium Extraction Facility, the new 7,000-square-meter site is slated to manufacture thorium-228, a precursor of lead-212, for radioligand therapies. . | Orano Med—developing targeted alpha therapies for cancer—kicked off construction of a 250 million euro plant in the Bessines-sur-Gartempe commune of France.
SUMMARY: The media loves to blame pharma companies for high healthcare costs, but unless we start to invest in healthy lifestyles, we’re headed for a healthcare crisis the likes of which we have never experienced. The media have targeted pharmaceutical companies for a long time because sensational headlines lead to clicks.
In the interview, conducted at CPHI Barcelona, Krishna Venkatesh, Global Head, Sterile Manufacturing Operations at Dr Reddy’s Laboratories explores industry’s growing focus on achieving end-to-end connectivity, as well as the potential of automation and track and trace solutions. What trends are you seeing in the pharma space?
As ISPE GAMP 5 Second Edition notes in the preface “Operating in a highly regulated industry may lead practitioners to apply prescriptive and rigid compliance-based approaches that are not commensurate with and not effective in managing any actual risk to the product and the patient.”
What are the top three trends that you are seeing in the biopharma manufacturing space? This resulted in not only a mismatch in the required manufacturing scale but also a significant over capacity as well. Let’s talk about continuous biopharma manufacturing. I believe this is going to be an emerging trend in the market.
2,3 Clinical implementation of CAR T-cell technology requires a reproducible T-cell manufacturing platform, which necessitates effective gene-transfer tools and T-cell culture conditions. Due to shipping and manufacturing requirements, the time from a patient being included in the CAR T programme to receiving therapy can be several weeks.
Supply chain shortages have dominated headlines for several months, and the pharma industry has been no exception. The pandemic effectively shut down supply chain paths overnight, and as a result, pharmaceutical manufacturers have faced delays and bottlenecks, which have caused drug shortages in healthcare systems.
The pharmaceutical supply chain is a global and complex network that includes a wide range of stakeholders such as pharmaceutical manufacturers, wholesale distributors, and pharmacy benefit managers (PBM), to ensure efficient and timely delivery of medications to the patients. Rise of pharma cold chain logistics companies.
o find out about the current trends in cell and gene therapy manufacturing, EPR spoke to Cell and Gene Therapy Catapult (CGT Catapult)’s Chief Manufacturing Officer, Stephen Ward, and Chief Business Officer, Jeanette Evans. Licensing of the manufacturing suites is expected in early 2024. So now we have a really nice blend.”
Intas Pharmaceuticals Ltd-Walk-In Drive for Manufacturing/ Packaging Department On 9th Sept’ 2022. Company Profile: INTAS Pharmaceutical is a leading, vertically integrated global pharmaceutical formulation development, manufacturing, and marketing company. Department: Solid Oral / Tablet Manufacturing.
Alembic Pharmaceuticals Ltd- Opening for Manufacturing / Engineering -Apply Now. is one of the leading API & Formulations manufacturing and marketing pharmaceutical Company. Departments: Manufacturing (Liquid), Engineering (Process Maintenance). Job Description. Alembic Pharmaceuticals Ltd. Qualification: B.
Manufacturing Optimization While the manufacturing industry lags behind others in terms of AI uptake, there is no shortage of potential ways to leverage this technology. It also has the potential to reduce the high carbon footprint associated with manufacturing.
In this blog post, you’ll learn: Why QR codes have made a comeback, When to use them, And, 8 ways to improve the patient experience and drive leads with QR codes. . Denso Wave is a leader in developing and manufacturing automatic data capture devices for barcodes, QR codes, and radio-frequency identification (RFID). .
Supply chain challenges take many forms in pharma – from capacity issues, to managing excess safety stock, and ensuring accurate supplier communication. These shocks can lead to unpredictable or even absent shipments, meaning drug production labs often aren’t dealing with a stable and regular volume of raw materials. About the author.
But how is this push shaping the pharma packaging market and what are the key changes we can expect to see? While manufacturers and packaging providers worldwide continue to put sustainability at the forefront of their projects, the pharmaceutical industry faces greater challenges than most. But how will this play out?
AMR certification: recognising responsibly in antibiotic manufacture Addressing access challenges for antimicrobials The second recommendation included in the report described establishing a sustainable access hub/s for antimicrobials to help address access challenges, especially in LMICs. “A
Its ability to accelerate R&D programmes, energise real-time clinical decision making and sharpen connections between pharma organisations and clients is clear and they can combine to positively impact patient outcomes. Pharma is a highly regulated industry and that is often why it is slow to adopt new technologies,” says Kazuki.
While Novo Nordisk struggles with manufacturing concerns and patient coverage on its long-acting insulin Levemir, Bayer missed a primary endpoint in a confirmatory trial for its P13K inhibitor Aliq | While Bayer's P13K Aliqopa couldn't prove its worth in a confirmatory trial, Novo's Levemir faced manufacturing issues and troubles with (..)
Nucleus on Tuesday revealed that it has signed its first manufacturing partnership with clinical-stage radiopharma player ARTBIO. The production deal will support ARTBIO’s planned phase 1 and 2 clinical trials of its lead program in prostate cancer, AB001.
We organize all of the trending information in your field so you don't have to. Join 8,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content